About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Study Predicts Fracture Risk After Women Stop Bisphosphonate Therapy

by Bidita Debnath on May 12, 2014 at 10:33 PM
Font : A-A+

 Study Predicts Fracture Risk After Women Stop Bisphosphonate Therapy

Over the next 5 years, age and testing of hip bone mineral density (BDM) when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures.

Bisphosphonates can reduce the risk of hip and spine fractures. But recent concerns about safety issues, including osteonecrosis of the jaw, atypical femoral fractures and esophageal cancer, have increased interest in interrupting or stopping bisphosphonate therapy after several years of treatment. This study tested methods for predicting fracture risk by measuring BMD using hip and spine duel-energy x-ray absorptiometry (DXA) and also bone turnover markers (BTMs) when women discontinue bisphosphonate therapy and a few years afterward.

Advertisement

The Fracture Intervention Trial Long-term Extension (FLEX) randomly assigned postmenopausal women (ages 61 to 86 years) previously treated with the bisphosphonate alendronate sodium (for four to five years) to five additional years of alendronate or placebo from 1998 through 2003. This analysis included only the placebo group. Hip and spine DXA were measured when the placebo was started and after one to three years of follow-up. Two different BTMs also were measured at baseline and after one and three years.

During five years of placebo, 22 percent of women (94 of 437) had one or more fractures; 82 had fractures after one year. Older age and lower hip BMD at the time alendronate therapy was discontinued were associated with higher rates of clinical fractures during the subsequent five years. However, neither BMD measures after one-year nor BTM levels one- to two -years after discontinuing alendronate were associated with fracture risk.
Advertisement

"Women with greater total hip bone loss two or three years after discontinuation may be at increased risk of fracture, but these results need to be confirmed in other studies before routine measurement of BMD after discontinuation of alendronate therapy can be recommended. In the meantime, short-term monitoring with BMD, BAP or NTX [two bone turnover markers] after discontinuation of four to five years of alendronate therapy does not appear to improve fracture prediction."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Know More About Mitochondria
Top 10 Foods for Decreasing DHT Production and Preventing Hair Fall
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Fracture Fracture of Knee Cap Reiki and Pranic Healing Colle’s Fracture Fracture Neck of Femur Screening for Osteoporosis Injuries Related to Sports Scaphoid Fracture of The Wrist Wrist Sprain Tibia (Shinbone) Shaft Fractures 

Most Popular on Medindia

Blood - Sugar Chart Pregnancy Confirmation Calculator The Essence of Yoga Vent Forte (Theophylline) Loram (2 mg) (Lorazepam) Sinopril (2mg) (Lacidipine) Daily Calorie Requirements Diaphragmatic Hernia Drug Side Effects Calculator Indian Medical Journals
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Study Predicts Fracture Risk After Women Stop Bisphosphonate Therapy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests